Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price271.00 GBp
Fair value166.35
Ethical score70.0/100
Our investment reviews on this name
2026-08-21Read Distribution293.50-7.7% to today ✓
2026-07-02Read Markup293.50-7.7% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Applied Nutrition Plc holds its Distribution at $271.00. The statistical read favours the sellers, held for 27 days.
As held on the ledger · 2026-09-18
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 27 days
Price at the screen
$271.00
Valuation
2,463.64 trailing · 2,006.22 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.00%
Below 33%
Interest-bearing debt is just 4.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
58.93%
Below 49%
Money owed to the company is 58.9% of assets, above the 49% limit.
Fail
Revenue purity
0.47%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Applied Nutrition Plc's business is fine, but its receivables are about 59% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in GBp, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. The price runs 38.6% above the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +22% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
APN.L trades on LSE (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution$271.00-7.7%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291. Since the last review it its composite score eased.
2026-09-21Distribution$293.50+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291.
2026-07-21Markup$293.50+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291.
2026-07-18Markup$293.50+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291.
2026-07-17Markup$293.50+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 128%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it none, with a mean price target of $291.
2026-07-03Markup$293.50+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$293.50Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$215.00
+32.8%
·
$1,328
+32.8%
2 months
$224.00
+27.5%
·
$1,275
+27.5%
3 months
$234.50
+21.8%
·
$1,218
+21.8%
6 months
$232.00
+23.1%
·
$1,231
+23.1%
1 year
$125.00
+128.4%
·
$2,284
+128.4%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever APN.L does next, these words stay.
Applied Nutrition Plc · APN.L · Distribution · $271.00
Recorded 2026-09-18 · before the outcome · scored mechanically